Patents Assigned to Universität Zurich
  • PDMS-Based Stretchable Multi-Electrode and Chemotrode Array for Epidural and Subdural Neuronal Recording, Electrical Stimulation and Drug Delivery
    Publication number: 20130303873
    Abstract: A hopper having a passage through which a medicine can be passed downward is provided. A part of a lower portion of the hopper is a deformable portion having flexibility, and the deformable portion is deformable so as to open and close the passage. According to this configuration, the deformable portion that is a part of the hopper is deformed to open and close the passage. Thus, there is no portion such as an opening and closing plate on which the medicine remains, thereby preventing a gap in which the medicine remains from being formed in the hopper, and preventing the medicine from easily remaining in the hopper.
    Type: Application
    Filed: June 14, 2011
    Publication date: November 14, 2013
    Applicants: UNIVERSITAT ZURICH, ETH ZURICH, ETH TRANSFER
    Inventors: Janos Vörös, Alexandre Larmagnac, Gregoire Courtine, Pavel Musienko
  • MODULATORS OF IL-12 AND/OR IL-23 FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20130302343
    Abstract: The invention provides antibody against p40, IL-12 or IL-23 for the prevention or treatment of Alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like-molecule, for the prevention or treatment of Alzheimer's disease. Similarly, siRNA, antisense or transcription factor modulators of gene expression of p19, p35, p40, IL-12R-?1, IL-12R-?2, and/or IL-23R for the prevention or treatment of Alzheimer's disease are provided.
    Type: Application
    Filed: January 4, 2012
    Publication date: November 14, 2013
    Applicants: CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN, UNIVERSITAT ZURICH
    Inventors: Burkhard Becher, Frank Heppner
  • USE OF PROKARYOTIC SPHINGOSINE-1-PHOSPHATE LYASES AND OF SPHINGOSINE-1-PHOSPHATE LYASES LACKING A TRANSMEMBRANE DOMAIN FOR TREATING HYPERPROLIFERATIVE AND OTHER DISEASES
    Publication number: 20130259851
    Abstract: The present invention relates to the use of prokaryotic sphingosine-1-phosphate lyases (S1PL) and S1PLs that lack a transmembrane domain or of a nucleic acid encoding such an S1PL in the prevention or treatment of a disease condition associated with elevated levels of sphingosine-1-phosphate (S1P), and for which S1P elevation is directly or indirectly causative. In addition, the invention relates to a new product in the form of S1PL lacking the N-terminal loop domain.
    Type: Application
    Filed: November 30, 2011
    Publication date: October 3, 2013
    Applicants: UNIVERSITAT ZURICH, UNIVERSITAT BERN
    Inventors: Uwe Zangemeister-Wittke, Andrea Huwiler, Markus G. Grutter, Florence Bourquin
  • Antibody (11C7) anti Nogo-A and its pharmaceutical use
    Patent number: 8535666
    Abstract: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant, 1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: September 17, 2013
    Assignees: Novartis AG, Universitat Zurich
    Inventors: Carmen Barske, Anis Khusro Mir, Thomas Oertle, Lisa Schnell, Martin E. Schwab, Alessandra Vitaliti, Mauro Zurini
  • BETA-HAIRPIN PEPTIDOMIMETICS
    Publication number: 20130189363
    Abstract: ?-Hairpin peptidomimetics of the general formula Cyclo (-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-), enantiomers and pharmaceutically acceptable salts thereof, with Xaa1-Xaa14 being amino acid residues of certain types which are defined in the description and the claims, have anti-infective activity, e.g. to selectively inhibit the growth of or to kill microorganisms such as Bacillus subtilis and/or Shigella boydii. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Application
    Filed: August 5, 2010
    Publication date: July 25, 2013
    Applicants: UNIVERSITÄT ZÜRICH, POLYPHOR AG
    Inventors: Daniel Obrecht, Frank Otto Gombert, John Anthony Robinson, Krystyna Patora-Komisarska
  • Uses of NOGO-A Inhibitors and Related Methods
    Publication number: 20130136737
    Abstract: The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.
    Type: Application
    Filed: July 8, 2011
    Publication date: May 30, 2013
    Applicants: UNIVERSITAT ZURICH, UNIVERSITE DE GENEVE
    Inventors: Pedro L. Herrera, Martin E. Schwab, Claire Bonal, Patrice Lalive D'epinay, Caroline Pot Kreis
  • Prevention of Bacterial Adherence and Growth in an Urological Implant
    Publication number: 20130123756
    Abstract: A medical device is disclosed, which comprises a functional unit (C) for permanent or temporary placement in the urogenital tract of a human or animal body. The functional unit has at least one electrically conducting portion. A power source (G) supplies a current to the electrically conducting portion after placement of the functional unit in the urogenital tract. In this manner, the growth of bacteria on the functional unit can be reduced.
    Type: Application
    Filed: July 6, 2011
    Publication date: May 16, 2013
    Applicants: ETH ZURICH, UNIVERSITAT ZURICH
    Inventors: Daniel Eberli, Lukas Hefermehl, Michael Gabi, Alexandre Lar-Magnac, Janos Voros
  • Drug delivery matrices to enhance wound healing
    Patent number: 8309518
    Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF? superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: November 13, 2012
    Assignees: Eidgenossische Technische Hochschule Zurich, Universitat Zurich
    Inventors: Jason C. Schense, Hugo Schmoekel, Jeffrey A. Hubbell, Franz Weber
  • Implant material
    Patent number: 8282911
    Abstract: The present relates to the field of dental and bone surgery. In particular, the invention relates to fibrous pharmaceutical compositions; fibrous webs, yarns and woven fabrics of such pharmaceutical compositions; to implant material essentially consisting of fibrous pharmaceutical compositions; to the manufacturing and use of such fibers/webs/implant materials.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: October 9, 2012
    Assignees: ETH Zürich, Universitat Zürich
    Inventors: Jan W. Stark, Oliver Schneider, Stefan Loher, Tobias Brunner, Marc Simonet, Patrick Schmidlin, Robert N. Grass
  • Treatment of scleroderma
    Patent number: 8247389
    Abstract: The present invention provides a method of treating scleroderma. The method consists in the upregulation of miR-29 by administration of miR-29 or a miR-29 upregulator which elevates circulating and/or intracellular concentrations of miR-29. The invention likewise relates to the use of miR-29 for such a treatment, and the use of miR-29 for the manufacture of a medicament for the treatment of scleroderma.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: August 21, 2012
    Assignee: Universitat Zurich Prorektorat MNW
    Inventors: Steffen Gay, Oliver Distler, Britta Maurer
  • RADIO-OPAQUE BIOACTIVE GLASS MATERIALS
    Publication number: 20120148646
    Abstract: Nanoparticulate material containing a matrix and embedded therein a radiopacifier are bioactive, show a high alkaline capacity and are radio-opaque. Compositions and formulations including such material are particularly useful in advanced dental applications, such as dental fillings and/or disinfection.
    Type: Application
    Filed: August 17, 2010
    Publication date: June 14, 2012
    Applicants: UNIVERSITAT ZURICH, ETH ZURICH
    Inventors: Wendelin Jan Stark, Dirk Mohn, Matthias Zehnder, Thomas Imfeld
  • REPEAT PROTEIN FROM COLLECTION OF REPEAT PROTEINS COMPRISING REPEAT MODULES
    Publication number: 20120142611
    Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.
    Type: Application
    Filed: December 19, 2011
    Publication date: June 7, 2012
    Applicant: UNIVERSITAT ZURICH
    Inventors: Michael Tobias STUMPP, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
  • Bioreactor system
    Patent number: 8192981
    Abstract: In one aspect the invention provides a bioreactor system for the production of tissue prostheses. The system includes a bioreactor, a culture medium reservoir coupled to the bioreactor by a first conduit and a second conduit, a pump operable to pump fluid into and draw fluid out of a pumping chamber defined in the bioreactor to generate a pulsatile flow of culture medium through the reservoir and bioreactor via said first and second conduits, one or more flow meters operable to generate flow rate signals representative of the rate of culture medium flow through one or both of said first and second conduits, and a controller arranged to receive said flow rate signals from said one or more flow meters and to control the pump means in response to said received flow rate signals to provide a desired rate of culture medium flow.
    Type: Grant
    Filed: November 24, 2006
    Date of Patent: June 5, 2012
    Assignee: Universität Zürich
    Inventors: Simon P. Hoerstrup, Gregor Zünd
  • Blockers of NMDA Receptor for the Treatment of Sickle Cell Anemia
    Publication number: 20120116060
    Abstract: Sickle cell anemia is a genetic disease characterized by red blood cells that assume an abnormal, rigid, sickle shape. Acute complications of Sickle cell anemia are treated symptomatically with analgesics and transfusions, and a prophylactic treatment of sickle cell crisis is long term application of hydroxyurea. According to the present invention, an N-methyl D-aspartate receptor (NMDAR) blocker is used for the treatment of sickle cell anemia and for manufacture of a medicament for the treatment of sickle cell anemia. Moreover, a method for screening for a compound effective in the treatment of sickle cell anemia comprises contacting a candidate compound with the NMDAR and selecting said candidate compound as effective if it is found to selectively reduce activity of the NMDAR.
    Type: Application
    Filed: April 18, 2010
    Publication date: May 10, 2012
    Applicant: Universitat Zurich
    Inventors: Anna Yulienva Bogdanova, Max Gassmann, Jeroen Goede
  • N-GLYCAN CORE BETA-GALACTOSYLTRANSFERASE AND USES THEREOF
    Publication number: 20120064541
    Abstract: The present invention relates to new galactosyltransferases, nucleic acids encoding them, as well as recombinant vectors, host cells, antibodies, uses and methods relating thereto.
    Type: Application
    Filed: May 28, 2010
    Publication date: March 15, 2012
    Applicants: ETH ZÜRICH, UNIVERSITÄT FÜR BODENKULTUR WIEN, UNIVERSITÄT ZÜRICH
    Inventors: Markus Künzler, Markus Aebi, Lain Wilson, Alexander Walter Titz, Michael Hengartner, Alex Butschi
  • Collections of repeat proteins comprising repeat modules
    Patent number: 8110653
    Abstract: A collection of repeat proteins, each repeat protein comprising a repeat domain, which comprises a set of consecutive repeat modules, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: February 7, 2012
    Assignee: Universitat Zurich
    Inventors: Michael Tobias Stumpp, Patrik Forrer, Hans Kasper Binz, Andreas Pluckthun
  • Magnetic field probe and method for manufacturing the same
    Patent number: 8093899
    Abstract: A magnetic field probe comprises a sample that exhibits magnetic resonance at an operating frequency, an electrically conductive structure surrounding the sample for receiving a magnetic resonance signal therefrom, and a solid jacket encasing the sample and the conductive structure. The jacket is made of a hardened two-component epoxy system containing a paramagnetic dopant dissolved therein, with the concentration of the dopant being chosen such that the jacket has a magnetic susceptibility that is substantially identical to the magnetic susceptibility of the conductive structure.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: January 10, 2012
    Assignee: Eidgenössische Technische Hochschule (ETH) and Universität Zürich
    Inventors: Christoph Barmet, Nicola De Zanche, Klass Prüssmann
  • TEMPLATE FIXED BETA-HAIRPIN LOOP MIMETICS AND THEIR USE IN PHAGE DISPLAY
    Publication number: 20110319291
    Abstract: Template-fixed ?-hairpin mimetics and libraries including a plurality of these mimetics are provided. The template-fixed ?-hairpin mimetics are of the following general formula: R1-Cys-Z-Cys-R2??I wherein the two cysteine residues are bridged by a disulfide bond, thereby forming a cyclic peptide; R1 and R2 are di- or tripeptide moieties of certain types, as defined herein; and Z is a chain of n amino acid residues with n being an integer from 4 to 20 and with each of these n amino acid residues being, independently, derived from any naturally occurring L-?-amino acid.
    Type: Application
    Filed: August 2, 2011
    Publication date: December 29, 2011
    Applicants: Universität Zürich, Polyphor Ltd.
    Inventors: Jan Wim Vrijbloed, Daniel Obrecht, Sergio Locurio, Frank Otto Gombert, Christian Ludin, Françoise Jung
  • Hanging Drop Plate
    Publication number: 20110306122
    Abstract: A hanging drop plate and a method of cultivating cells or of producing molecular aggregates in at least one liquid volume that adheres to a drop contact area of such a hanging drop plate. The hanging drop plate has a body with a first surface and a second surface that is essentially coplanar to the first surface. The second surface has a drop contact area for adherently receiving a liquid volume. The drop contact area is distinguished from a surrounding area by a relief structure that prevents spreading of the liquid volume on the second surface of the body. The body has at least one conduit that mouths into the drop contact area from the direction of the first surface of the body. A liquid volume is applied to the drop contact area through a communicating conduit. Cells and/or molecules can be introduced into this liquid volume.
    Type: Application
    Filed: September 22, 2008
    Publication date: December 15, 2011
    Applicant: Universitat Zurich Prorektorat Forschung
    Inventors: Wolfgang Moritz, Jens Kelm, Pierre-Alain Clavien, Simon Philip Hoerstrup
  • TEMPLATE FIXED BETA-HAIRPIN LOOP MIMETICS AND THEIR USE IN PHAGE DISPLAY
    Publication number: 20110294702
    Abstract: Template-fixed ?-hairpin mimetics and libraries including a plurality of these mimetics are provided. The template-fixed ?-hairpin mimetics are of the following general formula: R1-Cys-Z-Cys-R2??I wherein the two cysteine residues are bridged by a disulfide bond, thereby forming a cyclic peptide; R1 and R2 are di- or tripeptide moieties of certain types, as defined herein; and Z is a chain of n amino acid residues with n being an integer from 4 to 20 and with each of these n amino acid residues being, independently, derived from any naturally occurring L-?-amino acid.
    Type: Application
    Filed: August 2, 2011
    Publication date: December 1, 2011
    Applicants: UNIVERSITAT ZURICH, POLYPHOR LTD.
    Inventors: Jan Wim Vrijbloed, Daniel Obrecht, Sergio Locurio, Frank Otto Gombert, Christian Ludin, Françoise Jung